Novartis Diabetes Triple Drug Combination Deemed 'Irrational' In India
Executive Summary
Novartis’s plans for triple drug diabetes combination which includes vildagliptin have been turned down in India at least for now, with an expert panel questioning the rationale of such therapy.
You may also be interested in...
India Recommendation To Ban Irrational Drugs – Science Prevails But Calls To Go The Whole Hog
An Indian expert panel has recommended prohibiting over 300 "irrational" fixed dose combinations, reinforcing a previous ban on such products. Some stakeholders want such weeding out to be an ongoing exercise alongside fool-proofing the regulatory system.
India To Streamline Tiered Trial Approval Process – Will It Lift Sponsor Outlook?
India plans pivotal tweaks to its three-layered review process for clinical trial-related clearances – a move that is expected to pare approval timelines significantly and improve predictability for sponsors who have been generally cautious, over the recent past, about placing studies in the country.
Novartis Galvus India Case: Wockhardt Pulls Back?
Legal proceedings around Novartis' Galvus patent in India appear to have taken an interesting turn, with generic challenger Wockhardt indicating that it will retract its application for the revocation of the patent on the diabetes drug.